Share on StockTwits

Prothena Co. PLC (NASDAQ:PRTA) saw a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 763,327 shares, an increase of 41.4% from the April 15th total of 539,731 shares, American Banking News reports. Currently, 3.5% of the shares of the company are sold short. Based on an average daily volume of 835,091 shares, the days-to-cover ratio is presently 0.9 days.

In other Prothena Co. PLC news, Insider Tara Nickerson bought 1,656 shares of the company’s stock on the open market in a transaction that occurred on Monday, May 12th. The shares were purchased at an average price of $21.00 per share, for a total transaction of $34,776.00. Following the completion of the transaction, the insider now directly owns 2,000 shares in the company, valued at approximately $42,000. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

PRTA has been the subject of a number of recent research reports. Analysts at Wedbush upgraded shares of Prothena Co. PLC to a “best ideas list” rating in a research note on Friday, April 25th. Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Prothena Co. PLC in a research note on Thursday, April 24th. They now have a $60.00 price target on the stock. Finally, analysts at Citigroup Inc. initiated coverage on shares of Prothena Co. PLC in a research note on Wednesday, April 9th. They set a “buy” rating on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $43.75.

Prothena Co. PLC (NASDAQ:PRTA) opened at 20.93 on Monday. Prothena Co. PLC has a 1-year low of $9.14 and a 1-year high of $49.24. The stock’s 50-day moving average is $28.41 and its 200-day moving average is $29.41. The company’s market cap is $458.5 million.

Prothena Co. PLC (NASDAQ:PRTA) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.81 by $0.03.

Prothena Corporation PLC is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.